PapersFlow Research Brief
Inflammatory Bowel Disease
Research Guide
What is Inflammatory Bowel Disease?
Inflammatory bowel disease (IBD) is a group of idiopathic, relapsing inflammatory disorders of the gastrointestinal tract, classically including Crohn’s disease and ulcerative colitis.
Inflammatory bowel disease research spans population epidemiology, host genetics, mucosal immunology, and gut microbiome ecology, reflecting its heterogeneous clinical and biological drivers. The provided topic corpus contains 113,560 works on IBD, indicating a large and mature research literature, while the provided 5-year growth rate is N/A. Highly cited lines of evidence include global incidence/prevalence syntheses (e.g., "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies" (2017)) and mechanistic frameworks connecting genetics, immunity, and microbes (e.g., "Unravelling the pathogenesis of inflammatory bowel disease" (2007)).
Research Sub-Topics
NOD2 Genetics in Crohn's Disease
Frameshift and missense mutations in NOD2/CARD15 confer susceptibility to ileal Crohn's disease. Researchers investigate penetrance, gene-environment interactions, and functional consequences.
Gut Microbiota in IBD Pathogenesis
Dysbiosis featuring reduced Faecalibacterium prausnitzii and increased pathogens in Crohn's and UC. Researchers use 16S sequencing, metabolomics, and FMT trials to test causality.
Epidemiology of Inflammatory Bowel Disease
Rising incidence in newly industrialized regions and stable high rates in West; risk factors include smoking, appendectomy, and western diet. Researchers conduct population-based cohort studies tracking temporal trends.
NF-κB Signaling in IBD
Nuclear Factor-κB pathway mediates chronic mucosal inflammation through cytokine production and epithelial barrier dysfunction. Researchers target pathway inhibitors and study epithelial-intrinsic roles.
Anti-TNF Therapy in Crohn's Disease
Infliximab, adalimumab induction/maintenance regimens and predictors of primary/secondary loss of response. Researchers optimize dosing, combinations, and therapeutic drug monitoring strategies.
Why It Matters
IBD matters clinically because it is chronic, relapsing, and often requires long-term immunomodulatory therapy, and it matters scientifically because it is a tractable human model of dysregulated host–microbe immunity. Therapeutically, randomized trial evidence has directly shaped care: "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" (2002) established maintenance anti-TNF biologic therapy as a strategy for Crohn’s disease management, anchoring a major drug class used to control inflammatory activity and reduce relapse risk. Mechanistically, the field has produced actionable targets and biomarkers by linking pathways and microbial features to disease: Barnes and Karin (1997) in "Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases" positioned NF-κB signaling as a central transcriptional node in chronic inflammation including IBD, helping justify pathway-focused anti-inflammatory drug development. Microbiome studies have also motivated translational approaches to stratification and intervention: Frank et al. (2007) in "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" characterized disease-associated community imbalances, and Sokol et al. (2008) in "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients" identified a commensal with anti-inflammatory properties, supporting the rationale for microbiota-informed therapeutics and diagnostics.
Reading Guide
Where to Start
Start with "Unravelling the pathogenesis of inflammatory bowel disease" (2007) because it provides a unifying mechanistic scaffold (genetics, immunity, and microbes) that helps interpret why the later genetics, microbiome, and therapeutic trials are connected.
Key Papers Explained
A coherent reading path links population burden, mechanism, and intervention. Molodecky et al. (2011) in "Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review" and Ng et al. (2017) in "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies" define the global epidemiologic problem the field aims to address. Mechanistic causation is then anchored by genetics and immunity: Hugot et al. (2001) in "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease" and Ogura et al. (2001) in "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease" connect innate immune sensing to Crohn’s disease risk, while Barnes and Karin (1997) in "Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases" situates NF-κB as a key transcriptional driver of chronic inflammatory programs relevant to IBD. The host–microbe synthesis is made explicit by Jostins et al. (2012) in "Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease" and empirically supported by microbiome profiles in Frank et al. (2007) "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" and the protective-commensal signal in Sokol et al. (2008) "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients". Finally, translation to clinical practice is exemplified by Hanauer et al. (2002) in "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", which operationalizes immune pathway targeting as a maintenance strategy.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Advanced directions, constrained to the provided paper set, center on integrating multi-omic mechanism with treatment decisions: (1) connecting NOD2 and broader host–microbe genetic architecture (Hugot et al. (2001); Ogura et al. (2001); Jostins et al. (2012)) to microbiome-defined subtypes (Frank et al. (2007); Sokol et al. (2008)); (2) mapping NF-κB-centered inflammatory circuits (Barnes and Karin (1997)) onto patient heterogeneity summarized mechanistically by Xavier and Podolsky (2007) in "Unravelling the pathogenesis of inflammatory bowel disease"; and (3) using these mechanistic strata to inform when and for whom maintenance biologic therapy, as tested in Hanauer et al. (2002) "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial", is most appropriate.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Worldwide incidence and prevalence of inflammatory bowel disea... | 2017 | The Lancet | 5.6K | ✕ |
| 2 | Association of NOD2 leucine-rich repeat variants with suscepti... | 2001 | Nature | 5.6K | ✕ |
| 3 | A frameshift mutation in NOD2 associated with susceptibility t... | 2001 | Nature | 5.0K | ✓ |
| 4 | Host–microbe interactions have shaped the genetic architecture... | 2012 | Nature | 4.8K | ✓ |
| 5 | Increasing Incidence and Prevalence of the Inflammatory Bowel ... | 2011 | Gastroenterology | 4.7K | ✕ |
| 6 | Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic ... | 1997 | New England Journal of... | 4.7K | ✕ |
| 7 | Molecular-phylogenetic characterization of microbial community... | 2007 | Proceedings of the Nat... | 4.5K | ✓ |
| 8 | Unravelling the pathogenesis of inflammatory bowel disease | 2007 | Nature | 4.3K | ✕ |
| 9 | <i>Faecalibacterium prausnitzii</i> is an anti-inflammatory co... | 2008 | Proceedings of the Nat... | 4.2K | ✓ |
| 10 | Maintenance infliximab for Crohn's disease: the ACCENT I rando... | 2002 | The Lancet | 4.1K | ✕ |
In the News
Researchers discover new antibiotic for IBD - McMaster News
Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: They not only discovered a brand-new antibiotic that targets i...
New Groundbreaking IRCM Work Shows Promise for ...
Recherche du Québec**(FRQ). Emma Darbinian is also supported by the FRQ. The work was funded by the CRC2, the FRQ Clinical Research Scholars - Junior 1 Establishment Funds for Young Investigators, ...
Breakthrough IBD treatment clinical trial passes milestones
In 2023 Exosome BioSciences was awarded a $1.5 million grant from CUREator to develop novel exosome therapies to fund this clinical trial. CUREator is an Australian biotech incubator delivered by B...
Scientists develop molecules that may treat Crohn's disease
The molecules mimic a gene variant that protects against Crohn’s, demonstrating a roadmap for using genetics to develop therapies for inflammatory bowel disease and other chronic inflammatory disor...
Code & Tools
This package helps wrangle the clinical data in IBD Plexus. IBD Plexus is a data exchange platform designed to accelerate research toward finding c...
We trained high performing open source models on image scans of tissue biopsies to predict endoscopic categories in inflammatory bowel disease. The...
MaAsLin is a multivariate statistical framework that finds associations between clinical metadata and potentially high-dimensional experimental dat...
## Repository files navigation # Single cell RNAseq of inflammatory bowel disease patients Code repository for our paper.
This repository contains code and notebooks to reproduce the analyses for CCF medication effects across transcriptomics and proteomics. The work fo...
Recent Preprints
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
Inflammatory bowel disease (IBD) is a heterogeneous group of disorders characterized primarily by chronic relapsing intestinal inflammation, encompassing Crohn’s disease (CD) and ulcerative colitis...
Inflammatory bowel disease - Latest research and news
Inflammatory bowel disease is a chronic condition of unknown origin characterized by severe inflammation and mucosal destruction in the intestine. There are two main forms: Crohns disease, which c...
Fundamental and emerging insights into innate and ...
Inflammatory bowel diseases (IBD) are chronic and disabling disorders of the gastrointestinal tract of unknown aetiology, in which the pathologic process is triggered by multiple environmental and ...
Inflammatory Bowel Disease Therapeutics on the Rise
THE IQVIA INSTITUTE An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise. SEE LATEST REPORTS INSTITUTE REPORT Global Tr...
Probiotics and inflammatory bowel disease: an umbrella meta ...
Inflammatory Bowel Diseases (IBD) encompass chronic inflammatory conditions such as ulcerative colitis and Crohn’s disease. This umbrella meta-analysis investigates the efficacy of probiotic supple...
Latest Developments
Recent research highlights that new therapies and approaches are advancing in IBD, including the development of engineered probiotics to survive in inflamed colons, the use of GLP-1 receptor agonists to improve clinical outcomes and reduce hospitalization rates, and the approval of new biosimilars and IL-23 inhibitors by the FDA in 2025 (gastro.org, medcentral.com, medcentral.com). Additionally, groundbreaking studies include the development of molecules targeting protective gene variants and insights into the microbiota's role in disease mechanisms (broadinstitute.org, nature.com). As of February 2026, these developments indicate significant progress in understanding and treating IBD.
Sources
Frequently Asked Questions
What is inflammatory bowel disease (IBD)?
Inflammatory bowel disease (IBD) is a set of idiopathic, relapsing inflammatory disorders of the gastrointestinal tract, classically including Crohn’s disease and ulcerative colitis. Frank et al. (2007) in "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" described Crohn’s disease and ulcerative colitis as the two primary human IBDs.
How have incidence and prevalence of IBD changed over time worldwide?
Systematic reviews have documented increasing incidence and prevalence of IBD over time in multiple regions. Molodecky et al. (2011) in "Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review" synthesized evidence for temporal increases, and Ng et al. (2017) in "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies" extended this approach with population-based studies focused on the 21st century.
Which genetic findings most strongly link innate immunity to Crohn’s disease risk?
NOD2 variation is a central, highly cited genetic link between innate immune sensing and Crohn’s disease susceptibility. Hugot et al. (2001) in "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease" reported association of NOD2 leucine-rich repeat variants with Crohn’s disease, and Ogura et al. (2001) in "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease" identified a specific frameshift mutation associated with susceptibility.
How do host–microbe interactions shape IBD genetic architecture?
Large-scale genetic analyses support the idea that immune pathways involved in handling microbes have been under selection pressures that influence IBD risk loci. Jostins et al. (2012) in "Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease" explicitly framed IBD susceptibility as shaped by host–microbe interactions, connecting genetic architecture to microbial exposure and immune function.
Which microbiome signals are repeatedly implicated in Crohn’s disease and IBD?
Microbial community imbalance (dysbiosis) and loss of specific beneficial taxa are recurrent signals in IBD studies. Frank et al. (2007) in "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" reported microbial community imbalances in IBD, and Sokol et al. (2008) in "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients" identified F. prausnitzii as an anti-inflammatory commensal linked to Crohn disease microbiota profiles.
How does anti-TNF maintenance therapy fit into evidence-based Crohn’s disease management?
Randomized trial evidence supports maintenance biologic therapy as a core approach for controlling Crohn’s disease activity over time. Hanauer et al. (2002) in "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" tested maintenance infliximab in Crohn’s disease, providing a pivotal clinical-trial foundation for sustained anti-TNF treatment strategies.
Open Research Questions
- ? Which specific host genetic variants identified in "Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease" (2012) most directly map to modifiable microbial functions observed in "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" (2007)?
- ? How can NOD2 risk variation described in "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease" (2001) and "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease" (2001) be translated into patient-level stratification of treatment response to maintenance biologics studied in "Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial" (2002)?
- ? Which NF-κB-regulated cytokine programs emphasized in "Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases" (1997) best explain the transition from microbial imbalance to chronic mucosal inflammation summarized in "Unravelling the pathogenesis of inflammatory bowel disease" (2007)?
- ? Which microbial taxa or community configurations beyond Faecalibacterium prausnitzii, consistent with "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" (2007), are causally protective versus merely correlated with disease activity?
- ? How can global epidemiologic patterns compiled in "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies" (2017) be mechanistically reconciled with genetic architectures and host–microbe hypotheses proposed in "Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease" (2012)?
Recent Trends
Within the constraints of the provided data, the most visible trend signal is the scale and consolidation of the IBD literature: the topic corpus lists 113,560 works, and the most-cited papers emphasize (i) global epidemiologic synthesis (Ng et al. "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies"; Molodecky et al. (2011) "Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review"), (ii) immune-genetic mechanisms tied to microbial handling (Hugot et al. (2001) and Ogura et al. (2001) NOD2 papers; Jostins et al. (2012) "Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease"), and (iii) microbiome-centric explanations and candidate protective taxa (Frank et al. (2007) "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases"; Sokol et al. (2008) "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients").
2017The provided 5-year growth rate is N/A, so trend quantification beyond the works count is not supported by the supplied data.
Research Inflammatory Bowel Disease with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Inflammatory Bowel Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.